^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    RA123

    i
    Other names: RA123
    Associations

    News

    Trials
    Company:
    Sanofi
    Drug class:
    Glutaminase inhibitor
    Related drugs:
    Associations

    News

    Trials
    1year
    RA123, a new GLS1 allosteric inhibitor demonstrates in vitro and in vivo activity in multiple myeloma models (AACR 2023)
    In conclusion, this study demonstrated that RA123, a new specific GLS1 allosteric inhibitor was able to impact multiple myeloma tumor cell growth both in vitro and in vivo. This effect was associated with reduced glutamate pools and accumulation of glutamine levels within the tumor cells.
    Preclinical
    |
    GLS1 (Glutaminase)
    |
    RA123